CAJ | 학술논문

目的:评估18氟-氟代脱氧葡萄糖-正电子发射计算机断层显像(fluorine-18 fluorodeoxyglucose positron emission tomogra?phy,18F-FDG PET/CT)对接受4个周期阿霉素、博来霉素、长春新碱、达卡巴嗪(ABVD)方案化疗的霍奇金淋巴瘤(Hodgkin's lympho?ma,HL)患者预后的预测价值.方法:回顾分析2005年8月至2009年7月共62例初治的霍奇金淋巴瘤患者在接受4个周期ABVD方案化疗后18F-FDG PET/CT的检查结果,并与3年无事件生存率(EFS)、3年总生存率(OS)进行比较,评价其对接受4个周期AB?VD方案化疗的霍奇金淋巴瘤患者无事件生存的预测价值.结果:治疗结束后,PET/CT阳性患者18例,其中11例患者(61.1%)治疗失败,PET/CT阴性患者46例,其中5例患者(11.4%)治疗失败,PET/CT阳性组的治疗失败率显著高于阴性组(P<0.01).PET/CT阳性组和PET/CT阴性组患者的3年EFS分别是44.4%和81.8%(P<0.01),单因素分析显示PET/CT是霍奇金淋巴瘤患者3年EFS的独立预测因素(P<0.01).结论:PET-CT是预测HL患者在接受4个周期ABVD方案化疗后EFS的可靠方法.
목적:평고18불-불대탈양포도당-정전자발사계산궤단층현상(fluorine-18 fluorodeoxyglucose positron emission tomogra?phy,18F-FDG PET/CT)대접수4개주기아매소、박래매소、장춘신감、체잡파진(ABVD)방안화료적곽기금림파류(Hodgkin's lympho?ma,HL)환자예후적예측개치.방법:회고분석2005년8월지2009년7월공62례초치적곽기금림파류환자재접수4개주기ABVD방안화료후18F-FDG PET/CT적검사결과,병여3년무사건생존솔(EFS)、3년총생존솔(OS)진행비교,평개기대접수4개주기AB?VD방안화료적곽기금림파류환자무사건생존적예측개치.결과:치료결속후,PET/CT양성환자18례,기중11례환자(61.1%)치료실패,PET/CT음성환자46례,기중5례환자(11.4%)치료실패,PET/CT양성조적치료실패솔현저고우음성조(P<0.01).PET/CT양성조화PET/CT음성조환자적3년EFS분별시44.4%화81.8%(P<0.01),단인소분석현시PET/CT시곽기금림파류환자3년EFS적독립예측인소(P<0.01).결론:PET-CT시예측HL환자재접수4개주기ABVD방안화료후EFS적가고방법.
Objective: To evaluate the prognostic value of fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET/CT) after four cycles of chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) for Hodgkin's lymphoma (HL) patients. Methods: The data of 62 HL patients were retrospectively analyzed between August 2005 and July 2009. All patients underwent standard ABVD therapy. After four cycles of ABVD, the patients were evaluated with 18F-FDG PET/CT. The prognostic value of 18F-FDG PET/CT in HL was analyzed. Results: Treatment failure was seen in 11 of the 18 PET/CT-positive patients (61.1%) and in only 5 of the 46 PET/CT-negative patients (11.4%). The treatment failure rate in PET/CT-positive patients was significantly higher than in the PET/CT-negative ones (P<0.01). The three-year event-free survival (EFS) was 44.4% for PET/CT-positive patients and 81.8% for PET/CT-negative ones (P<0.01). Univariate survival analysis revealed that 18F-FDG PET/CT was the independent predictive factor of three-year EFS for patients with HL (P<0.01). Conclusion: After four cycles of ABVD chemotherapy, PET/CT is found to be an independent predictor of EFS in HL. However, due to the limited number of patients in this study, the conclusion needs to be confirmed.